Summary of patient treatment, responses, and pretreatment CXCL10 levels
Treatment group . | No. patients . | . | . | . | . | Mean CXCL10, pg/mL before therapy, ± SD . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Total . | SVR . | Nonresponders . | Breakthrough . | Relapse . | . | ||||
| A | 8 | 3 | 3 | 1 | 1 | 2421 ± 1324 | ||||
| B | 15 | 6 | 5 | 2 | 2 | 1894 ± 1468 | ||||
| C | 6 | 2 | 2 | 0 | 2 | 1802 ± 969 | ||||
| Total | 29 | 11 | 10 | 3 | 5 | 2020 ± 1322 | ||||
Treatment group . | No. patients . | . | . | . | . | Mean CXCL10, pg/mL before therapy, ± SD . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Total . | SVR . | Nonresponders . | Breakthrough . | Relapse . | . | ||||
| A | 8 | 3 | 3 | 1 | 1 | 2421 ± 1324 | ||||
| B | 15 | 6 | 5 | 2 | 2 | 1894 ± 1468 | ||||
| C | 6 | 2 | 2 | 0 | 2 | 1802 ± 969 | ||||
| Total | 29 | 11 | 10 | 3 | 5 | 2020 ± 1322 | ||||
Patients in groups A, B, and C received 48 weeks of treatment with pegylated IFNα-2a (Pegasys, Roche), 180 μg per week, by subcutaneous injection. Patients in treatment group B also received ribavirin (Copegus, Roche) at 1000 to 1200 mg/d in 2 divided doses based on body weight (those weighing > 75 kg received the higher dose). Patients in group C received pegylated IFNα-2a alone for the first 5 weeks, then received a further 48 weeks of therapy with pegylated IFNα-2a plus ribavirin dosed according to weight. There were no statistically significant differences in the response rates of patients in the 3 groups. The right-most column shows the mean CXCL10 levels (± SD) for each group at baseline. There was no statistically significant difference in the level of CXCL10 in pretreatment plasma samples from patients in the 3 groups.